Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Alcobra halts development of metadoxine for ADHD after failed Phase III trial; shares plunge

firstwordpharmaJanuary 18, 2017

Tag: Metadoxine , ADHD

PharmaSources Customer Service